Association between adherence to concomitant proton pump inhibitor therapy in current NSAID users and upper gastrointestinal complications

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 5, 2013, Pages 531-538

  Jonasson, Christian ^a   Hatlebakk, Jan G ^a   Lundell, Lars ^b   Kouri, Jukka P ^d   Andersen, Morten ^c   Granath, Fredrik ^c  

^a UNIVERSITY OF BERGEN   (Norway)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

adherence; bleeding; case control study; NSAID; peptic ulcer; proton pump inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; DUODENUM ULCER; FEMALE; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGISTER; RISK ASSESSMENT; RISK REDUCTION; STOMACH ULCER; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; EFFECT MODIFIER, EPIDEMIOLOGIC; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PEPTIC ULCER; PROTON PUMP INHIBITORS; RISK ASSESSMENT; SWEDEN;

EID: 84876408326     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835d5acd     Document Type: Article

References (36)

1. Fosbøl EL, Gislason GH, Jacobsen S, Abildstrom SZ, Hansen ML, Schramm TK, et al. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf 2008; 17:822-833.
2. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64:669-681. (Pubitemid 40559291)
3. Rostom ADC, Wells GA, Tugwell P, Welch V, Jolicoeur E, McGowan J, Lanas A. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; 4:CD002296.
4. Burmester G, Lanas A, Biasucci L, Hermann M, Lohmander S, Olivieri I, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis 2011; 70:818-822.
5. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332:1302-1308.
6. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296:1633-1644. (Pubitemid 44511610)
7. Ofman JJ, Maclean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2003; 49:508-518. (Pubitemid 36992191)
8. Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Pharmacol 2006; 47 (Suppl 1):S60-S66. (Pubitemid 44651787)
9. Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-1738. (Pubitemid 44893570)
10. García Rodríguez L, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:769-772. (Pubitemid 24098698)
11. Lanas A, Baron JA, Sandler RS, Horgan K, Bolognese J, Oxenius B, et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 2007; 132:490-497. (Pubitemid 46274654)
12. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T,Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-1255.
13. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:241-249.
14. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520-1528.
15. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364:665-674. (Pubitemid 39140622)
16. Tielemans MM, Eikendal T, Jansen JB, van Oijen MG. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf 2010; 33:443-453.
17. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998; 104 (Suppl 1):23S-29S. (Pubitemid 28186991)
18. Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, Ponce M, Alonso-Abreu I, Perez-Aisa MA, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009; 104:1633-1641.
19. Chan FK, Abraham NS, Scheiman JM, Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008; 103:2908-2918.
20. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104:728-738.
21. Rostom A, Moayyedi P, Hunt R. For the Canadian Association of Gastroenterology Consensus G. Canadian consensus guidelines on longterm nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 29:481-496.
22. Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010; 32:667-677.
23. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43:1905-1915.
24. Rostom A, Muir K, Dube C, Lanas A, Jolicoeur E, Tugwell P. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf 2009; 1:47-71.
25. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FKL, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101:701-710.
26. Van der Linden MW, Gaugris S, Kuipers EJ, Van den Bemt BJ, van Herk-Sukel MP, Herings RM. Gastroprotection among new chronic users of nonsteroidal anti-inflammatory drugs: a study of utilization and adherence in the Netherlands. Curr Med Res Opin 2009; 25:195-204.
27. Abraham NS, El-Serag HB, Johnson ML, Hartman C, Richardson P, Ray WA, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005; 129:1171-1178. (Pubitemid 41446857)
28. Van Soest EM, Sturkenboom MC, Dieleman JP, Verhamme KM, Siersema PD, Kuipers EJ. Adherence to gastroprotection and the risk of NSAIDrelated upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007; 26:265-275. (Pubitemid 46985490)
29. Van Soest EM, Valkhoff VE, Mazzaglia G, Schade R, Molokhia M, Goldstein JL, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 2011; 60:1650-1659.
30. Goldstein JL, Howard KB,Walton SM, McLaughlin TP, Kruzikas DT. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006; 4:1337-1345.
31. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11:450.
32. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16:726-735. (Pubitemid 47180362)
33. Holm SA. Simple sequentially rejective multiple test procedure. Scand J Statist 1979; 6:65-70.
34. Sturkenboom MC, Burke TA, Tangelder MJ, Dieleman JP, Walton S, Goldstein JL. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003; 18:1137-1147. (Pubitemid 38021600)
35. Laine L, Smith R, Min K, Chen C, Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006; 24:751-767.
36. Chang CH, Lin JW, Chen HC, Kuo CW, Shau WY, Lai MS. Non-steroidal anti-inflammatory drugs and risk of lower gastrointestinal adverse events: a nationwide study in Taiwan. Gut 2011; 60:1372-1378.